Towards Healthcare
U.S. Pharmaceutical Market to Drive USD 553.55 Bn by 2035

U.S. Pharmaceutical Market Transforming with New Therapies

Market insights predict the U.S. pharmaceutical industry will increase from USD 520.4 billion in 2025 to USD 965 billion by 2035, achieving a CAGR of 6.37%. The strong presence of pharmaceutical companies and favorable regulatory support bolsters market growth.

Content

  • Last Updated: 17 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The U.S. pharmaceutical market in 2026 is valued at USD 553.55 billion and is projected to climb to USD 965 billion by 2035, with a CAGR of 6.37% over the forecast period.

The Northeast region is leading the U.S. pharmaceutical market share by 38% due to the availability of state-of-the-art research and development facilities and the presence of key players.

The U.S. pharmaceutical market includes six segments by drug type, by therapy type, by formulation, by distribution channel, by manufacturer type, and by region.

Some key players include Pfizer, Inc., Gilead Sciences, and Eli Lilly and Company.

The US pharmacopoeia standards are built on deep science, provide a high degree of analytic rigor, and are accepted by regulators around the world.

Food and Drug Administration, National Institute of Health, Centers for Disease Control and Prevention, American Cancer Society
Any Questions